{"id":"enalapril-orodispersible-minitablet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Cough"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"1-5%","effect":"Hyperkalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting ACE, enalapril prevents the conversion of angiotensin I to the vasoconstrictor angiotensin II, which results in reduced systemic vascular resistance and lower blood pressure. It also reduces aldosterone secretion, decreasing sodium and water retention.","oneSentence":"Enalapril inhibits angiotensin-converting enzyme (ACE), reducing the production of angiotensin II and aldosterone, leading to vasodilation and decreased blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:29.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT02654678","phase":"PHASE2, PHASE3","title":"Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril","status":"UNKNOWN","sponsor":"Ethicare GmbH","startDate":"2016-03","conditions":"Heart Failure, Dilated Cardiomyopathy, Congenital Heart Disease","enrollment":100},{"nctId":"NCT02652741","phase":"PHASE2, PHASE3","title":"Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease","status":"UNKNOWN","sponsor":"Ethicare GmbH","startDate":"2016-01","conditions":"Heart Failure, Congenital Heart Disease","enrollment":50},{"nctId":"NCT02652728","phase":"PHASE2, PHASE3","title":"Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy","status":"UNKNOWN","sponsor":"Ethicare GmbH","startDate":"2016-01","conditions":"Heart Failure, Dilated Cardiomyopathy","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enalapril ODMT"],"phase":"phase_2","status":"active","brandName":"Enalapril Orodispersible Minitablet","genericName":"Enalapril Orodispersible Minitablet","companyName":"Ethicare GmbH","companyId":"ethicare-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enalapril inhibits angiotensin-converting enzyme (ACE), reducing the production of angiotensin II and aldosterone, leading to vasodilation and decreased blood pressure. Used for Hypertension, Heart failure.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}